title: Phase II trial of cisplatin and etoposide in patients with metastatic melanoma.
abstract: Fourteen patients with metastatic melanoma were treated with cisplatin and etoposide by bolus intravenous infusion daily for 5 consecutive days each month. All patients were evaluable for toxicity and twelve for response. Eight patients were treated with cisplatin 20 mg/m2 and etoposide 100 mg/m2 daily. Because of excessive myelosuppression, the daily dose of etoposide was reduced to 75 mg/m2 in the remaining six patients. There were no major responses among 12 evaluable patients (major response rate less than or equal to 24% with 95% confidence). The median time to progression was one month. One patient with a liver metastasis had a minor response lasting 6+ months. The combination of cisplatin and etoposide in these doses and schedule lacked sufficient clinical efficacy in the treatment of metastatic melanoma.
authors.affiliation: Division of Solid Tumor Oncology, Memorial-Sloan Kettering Cancer Center, New York, NY.
authors.forename: O
authors.initials: O
authors.lastname: Eton
authors.forename: D F
authors.initials: DF
authors.lastname: Bajorin
authors.forename: P B
authors.initials: PB
authors.lastname: Chapman
authors.forename: B V
authors.initials: BV
authors.lastname: Cody
authors.forename: A N
authors.initials: AN
authors.lastname: Houghton
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged
chemical_list: D005047:Etoposide; D002945:Cisplatin